Sustained activation of NRF2 can provoke resistance in chemotherapy on some tumor types, and in this view the degradation of β-transducin repeat-containing protein (β-TrCP)-NRF2 and KEAP1-NRF2 protein could be a potential methodology for enhancing chemosensitivity in cancer treatment [126]. Here, NFE2L2 is linked to cancer.